Description
Linvesta-EMP 5/25 Tablets combine linagliptin and empagliflozin, used to manage type 2 diabetes mellitus. Linagliptin is a DPP-4 inhibitor that increases insulin release and decreases glucose production by inhibiting the enzyme DPP-4. Empagliflozin is an SGLT2 inhibitor that enhances glucose excretion through urine, helping to lower blood sugar levels.
Dosage/Direction:
The recommended dose is 1 tablet (5/25) once daily, usually in the morning, with or without food. Dosage adjustments may be made based on individual blood glucose levels and overall response. It is crucial to follow your healthcare provider’s instructions for optimal effectiveness.
Side Effects:
Common side effects include urinary tract infections, increased urination, and gastrointestinal issues. Rare but severe side effects may include ketoacidosis, severe dehydration, or kidney problems. Contact your healthcare provider if you experience any serious or persistent symptoms.
